Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub

https://doi.org/10.64483/202522549

Mechanisms, Assessment, and Management of Drug-Induced Pigmentation in Clinical Pharmacology

Luay Alnughaymishi [(1)] , Fayez Homod AlSahabi [(2)] , Rawan Abdo Othman [(3)] , Sabah Hamoud O Alsuwat [(4)] , Moneerah Mohammed Humood Alzoman [(5)] , Faisal Abdullah Alghamdi [(6)] , Fahad Sami Abdulaziz Alfehaid [(7)] , Abdulaziz Salem Shafi Alshammari [(7)] , Hussam Ahmed Alhassan Alnami [(8)] , Saad Saud Saad Alrashoud [(9)] , Mufarh Abdullah Aldosari [(9)] , Mashael Abdullah Fahad Alamer [(9)] , Saleh Hassan M. Leslom[(9)]

(1) Buraidah – Qassim, Ministry of Health, Saudi Arabia,
(2) Pharmacy – Dental Surgery Focus, Ministry of Health, Saudi Arabia,
(3) Wadi Al-Dawasir General Hospital, Ministry of Health, Saudi Arabia,
(4) Wadi Al-Dwaser General Hospital, Ministry of Health, Saudi Arabia,
(5) King Fahad Medical City, Ministry of Health, Saudi Arabia,
(6) Ministry of Health, Saudi Arabia,
(7) Al-Ahsa Health Cluster, Ministry of Health, Saudi Arabia,
(8) Inventory Control – Asir Health Cluster, Ministry of Health, Saudi Arabia,
(9) AlAflaj General Hospital, Riyadh First Health Cluster, Ministry of Health, Saudi Arabia

Abstract

Background: Drug-induced pigmentation (DIP) is a clinically significant adverse effect resulting from diverse pharmacologic agents. It manifests through mechanisms such as melanogenesis stimulation, drug/metabolite deposition, and postinflammatory changes, often leading to cosmetic and psychosocial concerns.

Aim: To review the mechanisms, clinical assessment, and management strategies for DIP, emphasizing preventive and therapeutic approaches.

Methods: A comprehensive literature review was conducted, analyzing pharmacologic classes implicated in DIP, pathophysiologic mechanisms, histopathologic features, and treatment modalities. Clinical evaluation protocols and interprofessional management strategies were synthesized from current evidence.

Results: Over 50 drug classes, including antimicrobials, antimalarials, psychotropics, chemotherapeutics, and heavy metals, are associated with DIP. Mechanisms include enhanced melanogenesis, dermal deposition of lipophilic drugs, and inflammatory sequelae. Histopathology reveals nonspecific but diagnostic patterns, such as melanin-laden macrophages or drug granules. Management involves drug substitution or dose reduction, photoprotection, topical depigmenting agents, and procedural interventions like laser therapy. Prognosis is generally favorable, though pigmentation may persist, especially with dermal deposition or extracutaneous involvement.

Conclusion: Early recognition and individualized management of DIP are essential to prevent progression and optimize patient outcomes. Preventive strategies, patient education, and multidisciplinary collaboration remain critical components of care.

Keywords: Drug-induced pigmentation, hyperpigmentation, melanogenesis, pharmacologic adverse effects, dermatology, photoprotection, laser therapy.

Introduction

Drug-induced pigmentation (DIP) arises from a spectrum of pathophysiologic processes that alter normal skin color. The condition may result from increased melanin production, deposition of the drug or its metabolites, or postinflammatory changes. Stimulation of melanocytes is a primary mechanism, often triggered by chronic exposure to specific pharmacologic agents. This process leads to enhanced melanin synthesis, which can accumulate within the epidermis or dermis, producing varying degrees of hyperpigmentation. Additionally, some medications form complexes with iron or other metals in the skin, creating a distinct discoloration that can be persistent or progressive. In certain cases, the pigmentation occurs secondary to inflammatory processes, in which tissue injury and repair stimulate localized melanocyte activity, resulting in postinflammatory hyperpigmentation. Histopathologic examination often reveals nonspecific features, including increased melanin in basal keratinocytes, melanophages in the dermis, or direct deposition of drug-related substances. The precise distribution and intensity of pigmentation can

*Corresponding author e-mail: luay.alnughaymishi@gmail.com (Luay Alnughaymishi).
Receive Date: 07 December 2025, Revise Date: 29 December 2025, Accept Date: 31 December 2025

depend on drug class, dosage, duration of therapy, and individual patient susceptibility, including genetic predisposition, phototype, and concomitant sun exposure [1][2]. Pharmacologic classes most commonly implicated include cytotoxic agents, antimicrobials, antimalarials, antiarrhythmics, antipsychotics, and heavy metals. Recognition of these mechanisms is essential for clinicians and pharmacists, as early identification may prevent progression, guide therapeutic decisions, and inform patient counseling regarding potential reversibility or persistence of pigmentation. Additionally, understanding the mechanistic basis helps differentiate DIP from other dermatologic or systemic conditions that cause hyperpigmentation, including endocrinopathies, metabolic disorders, and chronic dermatoses. Further research is needed to elucidate molecular pathways and to develop interventions that can reverse or mitigate established pigmentation, particularly in cases where drug discontinuation is not feasible [1][2].

Etiology

Drug-induced pigmentation (DIP) arises from a wide range of pharmacologic agents and can manifest across multiple tissues, including the skin, mucous membranes, hair, and nails. The condition reflects the diverse mechanisms by which medications interact with pigmentary pathways, either by stimulating melanogenesis, causing direct deposition of the drug or its metabolites, or inducing postinflammatory changes. Anticoagulant therapy, such as eltrombopag, has been associated with hyperpigmentation in select patient populations. Antiepileptic drugs, including phenytoin and valproic acid, may produce diffuse or localized pigmentation changes, often dependent on cumulative dose and duration of therapy. Antimalarials, notably hydroxychloroquine, are well-documented to cause both cutaneous and mucosal pigmentation, typically after prolonged administration. Several antimicrobials are implicated in pigmentation, including clofazimine, dapsone, minocycline, isoniazid, levofloxacin, penicillin, and sulfonamides, with patterns ranging from bluish-gray to brown discoloration. Psychotropic medications, such as tricyclic antidepressants, mirtazapine, and phenothiazines, can provoke pigmentary changes due to melanocyte stimulation or metabolite deposition. Immunosuppressive agents, including tacrolimus and azathioprine, as well as antifungals like nystatin, voriconazole, and amphotericin B, have similarly been associated with hyperpigmentation in clinical practice. In the realm of antiviral and antiarrhythmic therapy, agents such as zidovudine, emtricitabine, and amiodarone are notable contributors [1].

Other drug classes linked to pigmentation include anti-inflammatory agents, notably nonsteroidal anti-inflammatory drugs and paracetamol, and prostaglandin analogs such as bimatoprost and latanoprost. Chemotherapeutic agents, including bleomycin, cisplatin, capecitabine, cyclophosphamide, doxorubicin, paclitaxel, and hydroxyurea, are frequently associated with both cutaneous and mucosal pigmentation changes, reflecting cumulative dosing effects and tissue-specific deposition. Exposure to heavy metals, including arsenic, iron, lead, silver, mercury, gold salts, and bismuth subsalicylate, also contributes to characteristic pigmentary alterations. Additionally, a diverse group of miscellaneous agents—including afamelanotide, hydroquinone, oral contraceptives, minoxidil, antimonial salts, iodides, niacin, pantoprazole, psoralens, simvastatin, deferoxamine, and cetirizine—have been reported to induce pigmentation changes in clinical settings [1]. The clinical presentation of DIP is highly variable, influenced by the specific agent, cumulative exposure, and patient-specific factors such as phototype and genetic predisposition. Variations are noted in the distribution pattern, color intensity and hue, and the persistence of pigmentation following drug discontinuation. Some pigmentary changes may be transient and reversible, whereas others, particularly those resulting from dermal deposition or chronic chemotherapeutic exposure, may persist for months to years, posing both therapeutic and cosmetic challenges. Recognition of the etiologic agent, awareness of high-risk drugs, and early identification of pigmentation patterns are essential for clinical management and patient counseling [1].

Epidemiology

Drug-induced pigmentation (DIP) represents a significant subset of acquired pigmentary disorders, accounting for an estimated 10% to 20% of cases attributed to exogenous factors [2]. Over fifty pharmacologic agents have been implicated in the development of pigmentation, spanning diverse therapeutic classes, including antimicrobials, antineoplastics, psychotropic agents, anticoagulants, antimalarials, and heavy metals. The wide variability in causative drugs reflects the complex interplay between medication properties, patient-specific factors, and cumulative exposure. The identification of the offending agent requires careful consideration of several variables. The latency between drug initiation and the onset of pigmentation is a key factor, with some agents producing changes within weeks, while others require months to years of exposure. A history of preceding inflammatory or phototoxic reactions often precedes pigmentary alterations and can help differentiate mechanisms of hyperpigmentation. The anatomical distribution of discoloration also provides clues regarding the underlying mechanism: pigmentary changes resulting from enhanced melanogenesis typically present as diffuse, photodistributed, or uniform darkening, whereas deposition of the drug or its metabolites within the dermis or epidermis often results in

localized hyperpigmentation on areas such as the face, hands, legs, palms, soles, or mucous membranes. Despite the broad spectrum of implicated medications, predicting which patients will develop clinically significant pigmentation remains challenging [3]. There is limited evidence to suggest a strong correlation between the risk of DIP and patient demographics such as sex, age, or race, although individuals with higher Fitzpatrick skin types may demonstrate more pronounced pigmentation due to the greater baseline melanin content [4]. Additional factors, including cumulative dose, drug metabolism, genetic predisposition, and concomitant use of photosensitizing medications, may further influence susceptibility. The variability in presentation and persistence of DIP underscores the need for prospective epidemiologic studies to better define risk profiles, elucidate mechanistic pathways, and inform targeted prevention and management strategies [5].



Fig. 1: Drug-induced pigmentation.

Pathophysiology

The pathophysiology of drug-induced pigmentation (DIP) is multifactorial and varies depending on the pharmacologic agent, its metabolites, and the individual patient's susceptibility. The primary mechanisms include stimulation of melanogenesis, direct deposition of the drug or its metabolites in the skin, postinflammatory pigmentary changes, and less commonly, vascular injury or lipofuscin accumulation. These processes may act independently or synergistically, producing variable clinical patterns and degrees of pigmentation. Enhanced melanin synthesis is a frequent mechanism underlying DIP. Certain medications directly stimulate melanocytes, leading to increased production and deposition of melanin within the epidermis. For example, afamelanotide and oral contraceptives exert a direct melanotropic effect, whereas drugs such as fluorouracil induce secondary hormonal changes, including elevated adrenocorticotropic hormone levels, which indirectly increase melanocyte activity [6]. This type of hyperpigmentation often manifests as diffuse or photodistributed darkening of the skin and may persist for months even after drug discontinuation. Direct deposition of drugs or their metabolites is another significant pathway. Lipophilic agents, including amiodarone, hydroxychloroquine, and minocycline, can accumulate within dermal macrophages or basal keratinocytes, forming pigmented complexes. This deposition frequently results in slate-gray, blue, or brown discoloration and may involve sun-exposed and non–sun-exposed areas, depending on the drug's affinity for melanin or dermal tissues [7][8]. In some cases, these pigments resemble tattoo-like deposits and may remain long-term despite cessation of therapy.



Fig. 2: Doxorubicin-induced pigmentation.

Inflammatory mechanisms also contribute to pigmentation. Certain agents induce cutaneous inflammation, erythema, or drug-related eruptions, which subsequently evolve into postinflammatory hyperpigmentation. Bleomycin-induced flagellate erythema exemplifies this mechanism, where linear erythematous lesions resolve into persistent hyperpigmentation. Photosensitizing drugs, such as tetracyclines, exacerbate ultraviolet-induced damage, creating superficial burns that trigger pigmentary deposition. Additional mechanisms include vascular injury, which promotes hemosiderin deposition and localized pigmentation, and the accumulation of lipofuscin, a pigment composed of oxidized lipids and proteins resistant to degradation. These latter pathways are less common but contribute to the variability and persistence of DIP in some patients [9]. Understanding these diverse mechanisms is essential for clinicians to anticipate, identify, and manage DIP effectively, as the clinical presentation and prognosis are closely linked to the underlying pathophysiologic processes [7][8][9].

Histopathology

Histopathologic evaluation of drug-induced pigmentation (DIP) demonstrates significant variability that reflects the causative agent, underlying pathogenic mechanism, and site of pigment deposition. The microscopic features of DIP are often nonspecific, yet careful examination can provide clues regarding the implicated drug and mechanism. Antimalarial agents, such as hydroxychloroquine, typically localize within the deep dermis, frequently in perivascular regions or

within macrophages surrounding capillaries. This deposition pattern reflects the drug's affinity for melanin and connective tissue components, producing a slate-gray or blue pigmentation that correlates clinically with long-term use. Amiodarone-induced pigmentation is characterized histologically by lipofuscin accumulation. Lipofuscin granules are evident within histiocytes and perivascular areas, representing the oxidation of lipids and proteins secondary to prolonged drug exposure. The pigmentation often presents as a blue-gray discoloration in sun-exposed areas, particularly the face and forearms. Tetracycline-related pigmentation demonstrates basal layer hyperpigmentation with melanin-laden dermal macrophages. This pattern typically follows photodistributed areas and is accentuated by ultraviolet exposure, consistent with the drug's photosensitizing properties. Cytotoxic agents such as doxorubicin and bleomycin produce distinctive histologic findings. Doxorubicin induces increased epidermal melanin deposition, predominantly in basal and suprabasal layers, whereas bleomycin enhances melanin concentration across multiple layers of the epidermis. These changes are often accompanied by postinflammatory alterations, particularly if drug-induced erythema preceded pigmentation. Heavy metals exhibit unique deposition patterns that are readily identifiable histologically. Mercury accumulates in the upper dermis, basal epidermis, and within dermal melanophages. Silver forms fine granules within the lamina propria and sweat glands, while gold deposits appear as large, rounded granules surrounding dermal vessels. These patterns are highly characteristic and can assist in differentiating the causative agent from other pigmentary disorders [10]. Overall, histopathologic evaluation is a valuable adjunct in confirming DIP, elucidating the underlying mechanism, and guiding clinical management, particularly in cases of persistent, generalized, or atypical pigmentation [10].

History and Physical

The evaluation of suspected drug-induced pigmentation (DIP) necessitates a detailed and structured clinical assessment to accurately identify the causative agent and guide management. A comprehensive medication history is the cornerstone of this evaluation and should include prescription medications, over-the-counter drugs, supplements, and complementary or homeopathic agents, as seemingly innocuous substances such as nonsteroidal anti-inflammatory drugs may contribute to pigmentation changes. The temporal relationship between drug initiation and the onset of pigmentation should be carefully documented, as many cases of DIP develop insidiously over months to years. For instance, hydroxychloroquine-related pigmentation often emerges after an average of six years of continuous therapy, highlighting the importance of longitudinal medication history [11]. Physical examination should systematically assess the skin, mucous membranes, nails, and hair. Special attention should be given to patterns of pigmentation, particularly in sun-exposed areas, which may provide diagnostic clues. Certain drugs produce characteristic morphologies; for example, bleomycin can induce flagellate erythema, whereas tetracyclines often cause photodistributed hyperpigmentation. The color of the pigmentation also informs the underlying mechanism. Hypermelanosis typically manifests as brown pigmentation, whereas direct deposition of drug or metabolites produces gray, blue, or violaceous discoloration. Depth of pigment deposition often correlates with hue, aiding in distinguishing epidermal versus dermal involvement. Dose-response relationships are another critical consideration, as pigmentation frequently intensifies with cumulative drug exposure. Clinicians should be aware that DIP is largely a diagnosis of exclusion, requiring careful differentiation from other acquired pigmentary disorders such as melasma, postinflammatory hyperpigmentation, or endocrine-related pigmentation. The increasing diversity of implicated pharmacologic agents, including novel biologics and chemotherapeutics, underscores the need for ongoing vigilance. Where clinically feasible, discontinuation of the suspected agent, combined with photoprotection strategies and serial monitoring for improvement, not only aids in establishing causality but also forms the basis of early management and prevention of progression. This structured approach ensures accurate identification, appropriate intervention, and optimal patient outcomes [10].

Evaluation

The evaluation of drug-induced pigmentation (DIP) relies primarily on a meticulous clinical assessment, supported by selective diagnostic tools to confirm the etiology and exclude alternative causes. A thorough history and physical examination remain the cornerstone of diagnosis, providing essential information regarding medication exposure, duration of use, cumulative dose, and the temporal onset of pigmentation relative to therapy. Recognition of characteristic distribution patterns, color, and morphology often offers important diagnostic clues, particularly when linked to specific pharmacologic classes [12]. Adjunctive diagnostic modalities can enhance clinical evaluation. Dermoscopy allows visualization of pigment depth, distribution, and pattern, aiding in differentiation between epidermal and dermal pigmentation as well as distinguishing melanin from drug or metal deposits. Histopathologic examination provides additional confirmation by identifying intracellular or extracellular pigment deposition, the presence of melanophages, and associated inflammatory or vascular changes. Specific stains can distinguish between melanin,

hemosiderin, and exogenous drug or heavy metal deposits, offering insight into the underlying pathophysiology [12].

Laboratory and imaging studies may be warranted to assess systemic effects of the implicated drug, particularly in cases associated with chemotherapeutic agents, antimalarials, or heavy metals. Evaluations such as liver function tests, renal panels, and iron studies can identify metabolic or organ-related complications that may influence pigmentation or overall patient safety [13][14]. Despite these tools, the diagnosis of DIP remains largely clinical, dependent on the temporal relationship between drug exposure and pigmentary change, as well as improvement following drug discontinuation. Establishing this causal link is often the most reliable diagnostic indicator in routine practice. Ongoing research is required to refine diagnostic approaches, improve the specificity of histologic and imaging techniques, and develop standardized protocols for monitoring and managing DIP. Enhancing the precision of evaluation methods will facilitate earlier recognition, allow targeted interventions, and ultimately improve patient outcomes in the context of increasingly complex pharmacologic regimens.

Treatment / Management

The management of drug-induced pigmentation (DIP) requires a structured and individualized approach, beginning with an assessment of the causative agent and consideration of alternatives that maintain therapeutic efficacy while reducing the risk of continued pigmentation. When clinically feasible, substitution of the offending drug with another agent that has a lower propensity for inducing pigmentation is the preferred strategy. This approach is particularly relevant for medications such as amiodarone, hydroxychloroquine, and minocycline, which exhibit a well-documented dose-dependent relationship with pigmentation. In cases where substitution is not possible, gradual dose reduction may be employed, ensuring that the underlying disease process remains adequately controlled. Dose tapering has been associated with partial resolution or attenuation of dyschromia, particularly in long-term therapies where cumulative drug exposure has contributed to more pronounced pigmentary changes. Preventive strategies play a critical role in minimizing further pigmentation. Ultraviolet (UV) radiation significantly exacerbates pigmentary changes, especially in drugs that are photoactive or photoaccentuated. Patients receiving antimalarials, psychotropic agents, tetracyclines, or amiodarone should be counseled on rigorous photoprotection measures, including avoiding direct sunlight, wearing broad-spectrum sunscreen, and using protective clothing. Such interventions not only reduce the progression of pigmentation but also may enhance the efficacy of subsequent therapeutic measures. Patient education on lifestyle modifications and avoidance of contributing environmental factors is an essential adjunct to medical management [15].

Topical therapies constitute a cornerstone of direct pigment-targeted intervention. Agents such as hydroquinone, high-potency corticosteroids, and calcineurin inhibitors like tacrolimus are commonly utilized to reduce melanin production and achieve lightening of hyperpigmented areas. Chemical peels with strong α-hydroxy acids have also demonstrated efficacy in selected cases. The choice of topical therapy must account for the underlying pathogenic mechanism: pigmentation due to melanin hyperproduction generally responds better to depigmenting agents, whereas drug or metabolite deposition in the dermis often exhibits limited responsiveness to topicals due to the deeper localization of pigment [15]. Careful monitoring is necessary to avoid adverse effects such as rebound hyperpigmentation, irritation, or ochronosis with prolonged hydroquinone use. For cases refractory to conservative measures or involving deeper pigment deposition, procedural interventions such as laser therapy have been increasingly employed. Various laser modalities, including picosecond, Q-switched, alexandrite, and ruby lasers, have shown efficacy in disrupting dermal pigment granules, particularly in psychotropic drug-induced pigmentation. Additional approaches, including Nd:YAG lasers, carbon dioxide full-face resurfacing, dermabrasion, chelation therapy, and intense pulsed light (IPL), have been described with variable outcomes [16]. While these modalities may accelerate pigment reduction, complete resolution is not always achievable, and residual discoloration may persist for years despite multimodal treatment. Procedural interventions should be selected based on pigment depth, distribution, and patient tolerance, with expectations managed appropriately.

Long-term follow-up is crucial for assessing therapeutic response, preventing recurrence, and monitoring for potential complications. Regular clinical evaluation allows for early identification of persistent or progressive pigmentation, adjustment of topical or procedural interventions, and reinforcement of photoprotection. Additionally, coordination with the prescribing clinician is essential to balance ongoing disease management with efforts to minimize pigmentary sequelae. Multidisciplinary collaboration involving dermatologists, pharmacists, and primary care or specialty providers enhances outcomes, ensuring that both the primary medical condition and DIP are managed optimally. In conclusion, the management of drug-induced pigmentation is multifaceted, combining drug modification strategies, preventive measures, topical and procedural therapies, and ongoing patient education. The approach must be individualized according to the causative agent, mechanism of pigmentation, and patient-specific factors. Although

treatment can lead to significant improvement, pigmentary changes may persist, underscoring the importance of early recognition, preventive strategies, and patient counseling to mitigate long-term cosmetic and psychosocial impact [15][16].

Differential Diagnosis

Drug-induced pigmentation (DIP) is fundamentally a diagnosis of exclusion, requiring careful consideration of other potential etiologies that can produce hyperpigmentation. Accurate differentiation is essential, as misattribution may lead to inappropriate management or delayed recognition of underlying systemic disorders. Primary pigmentary disorders, such as melasma, are among the most frequently encountered conditions that must be excluded, particularly in cases involving the face. Melasma typically presents as symmetric, hyperpigmented macules on sun-exposed areas and may be influenced by hormonal factors, making clinical history and distribution patterns important in distinguishing it from drug-induced changes. Endocrine and metabolic disorders also warrant evaluation in the differential diagnosis. Addison disease can produce diffuse hyperpigmentation due to increased melanocyte-stimulating hormone levels, often accompanied by systemic manifestations such as hypotension and electrolyte disturbances. Hemochromatosis, characterized by excessive iron accumulation, can present with bronzing of the skin and involvement of visceral organs, necessitating laboratory assessment of iron studies. Similarly, Wilson disease, a disorder of copper metabolism, may rarely manifest with cutaneous pigmentation alongside hepatic and neurologic findings. Nutritional deficiencies, such as pellagra secondary to niacin deficiency, can produce characteristic pigmentation on sun-exposed regions including the chest, back, and extremities, often accompanied by gastrointestinal and neurologic symptoms. Additional dermatologic conditions may mimic DIP, including lichen planus pigmentosus and oral lichenoid reactions, which can result in localized or diffuse pigmentation of the skin and mucous membranes. These conditions often exhibit a violaceous or slate-gray hue and may be accompanied by pruritus or mucosal lesions, providing clinical clues to their etiology. Comprehensive evaluation, including detailed medication history, physical examination, and selective laboratory or histologic investigations, is critical to exclude these alternative causes. Accurate differentiation ensures that DIP is correctly identified and appropriately managed, preventing unnecessary discontinuation of essential medications while addressing coexisting systemic or dermatologic disorders [17].

Prognosis

The prognosis of drug-induced pigmentation (DIP) is generally favorable, particularly when the condition is confined to the skin and recognized early. Most cases are benign and asymptomatic, posing primarily cosmetic concerns rather than systemic health risks. Patients often experience psychological and social effects, including reduced self-esteem and body image dissatisfaction, which can vary in severity depending on the visibility of affected areas and patient perception [18]. Early identification of the causative agent and appropriate management—such as drug substitution, dose reduction, or photoprotection—can mitigate the extent of pigmentation and prevent further progression. Extracutaneous involvement, however, can complicate prognosis. Pigmentation affecting nails, mucous membranes, or oral structures may be more resistant to treatment and persist longer despite drug discontinuation. In these scenarios, therapeutic options are limited, and the condition may present a long-term cosmetic challenge. In addition, certain medications may produce pigmentary changes in internal organs, although such cases are rare. For instance, hydroxychloroquine can induce retinal pigmentation, particularly in the macula, potentially leading to bull's-eye retinopathy and visual impairment. Recognition of extracutaneous involvement requires vigilant monitoring, as delayed detection can have functional implications beyond cosmetic concerns. Overall, DIP does not increase mortality, and most patients regain satisfaction with management interventions; however, the potential for persistent pigmentation, particularly in high-risk anatomic sites, underscores the importance of early detection, continuous monitoring, and patient counseling [18].

Complications

Although DIP is generally considered a benign adverse effect, several complications may arise, primarily related to delayed recognition or atypical presentations. The gradual onset of pigmentation often leads to misdiagnosis or underreporting, particularly in patients receiving multiple medications. Misattribution may result in unnecessary investigations or prolonged exposure to the causative agent. While the majority of cases are asymptomatic, pigmentation associated with inflammatory drug reactions, such as fixed drug eruptions or flagellate erythema, can involve pruritus, discomfort, or localized erythema. Similarly, lichen planus pigmentosus may present with mucosal involvement, further complicating management and treatment decisions [19]. Extracutaneous pigmentation constitutes another potential complication. Hydroxychloroquine-induced retinal pigmentation exemplifies a clinically significant manifestation, where pigment deposition in the macula can lead to irreversible vision changes if detected late. Minocycline-related pigmentation of internal organs, including the heart valves or liver, is rare but has been documented in case reports, highlighting the need for awareness among

prescribing clinicians. In such scenarios, routine monitoring may prevent progression to clinically significant dysfunction. Furthermore, pigmentation persisting after drug discontinuation may not fully resolve, leading to long-term cosmetic concerns that impact patient quality of life. Although DIP is not inherently life-threatening, these complications emphasize the need for early detection, accurate diagnosis, and patient-centered management strategies to minimize both aesthetic and functional sequelae [19].

Patient Education

Patient education is a central component in managing DIP, beginning with the initial identification of pigmentation and continuing throughout treatment and follow-up. Patients must provide a detailed account of all medications, including prescription, over-the-counter, and complementary therapies, to facilitate accurate identification of the causative agent. Understanding the temporal relationship between drug exposure and pigmentation is essential for clinicians to assess risk and implement appropriate management strategies [20]. When discontinuation or dose reduction of the offending medication is indicated, patients should receive clear instructions regarding the revised treatment plan to prevent exacerbation and maintain therapeutic control of the underlying condition. Preventive strategies are critical in minimizing the severity and progression of DIP. Photoprotection measures, including strict sun avoidance, use of broad-spectrum sunscreen, and wearing protective clothing, are particularly important for patients on medications with UV-enhanced pigmentation risk, such as antimalarials, amiodarone, and tetracyclines. Patients should also be informed about the expected course of pigmentation, emphasizing that it may persist for months or years even after drug cessation and that treatment interventions, whether topical, systemic, or procedural, may not fully restore baseline skin color. Empowering patients with knowledge regarding prognosis, preventive strategies, and ongoing monitoring enhances adherence, facilitates early reporting of new pigmentary changes, and supports shared decision-making in the management of DIP [19][20].

Enhancing Healthcare Team Outcomes

Effective management of drug-induced pigmentation (DIP) relies on a coordinated, interprofessional approach to optimize patient care and prevent recurrence. Dermatologists play a central role in evaluating the extent and pattern of pigmentation, determining the likely causative agents, and recommending appropriate interventions. Collaboration with primary care physicians, who often prescribe the implicated medications, is essential to implement strategies such as dose reduction, drug substitution, or discontinuation while ensuring the underlying condition remains adequately controlled. Clear documentation of a patient's history of DIP is critical for guiding future prescribing decisions, reducing the risk of repeated exposure, and informing both acute and long-term management plans. Pharmacists contribute by reviewing medication histories, identifying potential drug interactions, and advising clinicians on alternative agents that may mitigate the risk of pigmentation. Specialty-trained nurses provide ongoing monitoring, patient education, and assessment of treatment adherence, including the implementation of photoprotection strategies and topical or procedural interventions. Timely recognition of DIP by all members of the healthcare team allows for early intervention, which may prevent progression of pigmentation and improve patient outcomes. Interprofessional communication also supports patient-centered care, enabling shared decision-making and providing patients with comprehensive information about prognosis, treatment options, and preventive measures. Coordinated care ensures that therapeutic goals, such as controlling the underlying disease while minimizing cosmetic and psychosocial consequences of DIP, are achieved. This integrated approach enhances healthcare team efficiency, fosters consistency in management strategies, and improves overall patient satisfaction, highlighting the importance of multidisciplinary collaboration in the effective management of drug-induced pigmentation [20].

Conclusion:

Drug-induced pigmentation represents a multifactorial condition with significant cosmetic and psychosocial implications. Although generally benign, its persistence and variability necessitate early identification and proactive management. Clinicians must maintain vigilance when prescribing high-risk medications, particularly those with cumulative dose-dependent effects such as antimalarials, psychotropics, and chemotherapeutics. A structured approach—comprising detailed medication history, physical examination, and selective diagnostic tools—facilitates accurate diagnosis and differentiation from other pigmentary disorders. Management should prioritize discontinuation or substitution of the offending drug when feasible, coupled with rigorous photoprotection to mitigate progression. Topical depigmenting agents and procedural interventions, including laser therapy, offer therapeutic benefit, though complete resolution may remain elusive in cases involving dermal deposition. Patient education is paramount, ensuring adherence to preventive measures and realistic expectations regarding treatment outcomes. Ultimately, DIP underscores the importance of interprofessional collaboration among dermatologists, pharmacists, and primary care providers to balance therapeutic efficacy with cosmetic considerations. Continued research into molecular mechanisms and targeted therapies will enhance future management strategies, reducing the

long-term impact of this condition on patient quality of life.

References:

1. Tisack A, Mohammad TF. Drug-Induced Pigmentation: A Review. Drugs. 2024 Sep:84(9):1071-1091. doi: 10.1007/s40265-024-02062-z.
2. Giménez García RM, Carrasco Molina S. Drug-Induced Hyperpigmentation: Review and Case Series. Journal of the American Board of Family Medicine : JABFM. 2019 Jul-Aug:32(4):628-638. doi: 10.3122/jabfm.2019.04.180212.
3. Nahhas AF, Braunberger TL, Hamzavi IH. An Update on Drug-Induced Pigmentation. American journal of clinical dermatology. 2019 Feb:20(1):75-96. doi: 10.1007/s40257-018-0393-2.
4. Halder RM, Nandedkar MA, Neal KW. Pigmentary disorders in ethnic skin. Dermatologic clinics. 2003 Oct:21(4):617-28, vii
5. Dereure O. Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. American journal of clinical dermatology. 2001:2(4):253-62
6. Schaefer JK, Ramnath N. Fluorouracil-Induced Hyperpigmentation. The New England journal of medicine. 2020 Jan 23:382(4):e6. doi: 10.1056/NEJMicm1909329.
7. Peng JP, Yang XY, Luo F, Yuan XM, Xiong H, Ma WK, Yao XM. Hydroxychloroquine-induced hyperpigmentation of the skin and bull's-eye maculopathy in rheumatic patients: a case report and literature review. Frontiers in immunology. 2024:15():1383343. doi: 10.3389/fimmu.2024.1383343.
8. Nishikubo M, Yamashita D, Nishioka H. Minocycline-induced skin hyperpigmentation. BMJ case reports. 2025 Mar 25:18(3):. pii: e264463. doi: 10.1136/bcr-2024-264463. Ep
9. Bell AT, Roman JW, Gratrix ML, Brzezniak CE. Minocycline-Induced Hyperpigmentation in a Patient Treated with Erlotinib for Non-Small Cell Lung Adenocarcinoma. Case reports in oncology. 2017 Jan-Apr:10(1):156-160. doi: 10.1159/000452146.
10. Granstein RD, Sober AJ. Drug- and heavy metal--induced hyperpigmentation. Journal of the American Academy of Dermatology. 1981 Jul:5(1):1-18
11. Kounis NG, Frangides C, Papadaki PJ, Zavras GM, Goudevenos J. Dose-dependent appearance and disappearance of amiodarone-induced skin pigmentation. Clinical cardiology. 1996 Jul:19(7):592-4
12. Behera B, Palit A, Sethy M, Nayak AK, Dash S, Ayyanar P. Dermoscopic features of clofazimine-induced pigmentation in a borderline tuberculoid leprosy plaque. Indian journal of dermatology, venereology and leprology. 2021 Jan-Feb:88(1):85-87. doi: 10.25259/IJDVL_1421_20.
13. Hamri L. Hyperpigmentation Induced by Hydroxychloroquine. Dermatology practical & conceptual. 2023 Oct 1:13(4):. doi: 10.5826/dpc.1304a235.
14. Baaklini C, Kesav N, Reinhart W. Minocycline-Induced Ocular Ochronosis. Cureus. 2023 Aug:15(8):e43307. doi: 10.7759/cureus.43307.
15. Suvirya S, Agrawal A, Parihar A. 5-Fluorouracil-induced bilateral persistent serpentine supravenous hyperpigmented eruption, bilateral mottling of palms and diffuse hyperpigmentation of soles. BMJ case reports. 2014 Oct 21:2014():. doi: 10.1136/bcr-2014-206793.
16. Hamid RN, Yang RG, Munavalli GS. Treatment of imipramine-induced hyperpigmentation with quality-switched ruby and picosecond lasers. JAAD case reports. 2021 Nov:17():12-17. doi: 10.1016/j.jdcr.2021.09.004.
17. Yamaguchi Y, Hearing VJ. Melanocytes and their diseases. Cold Spring Harbor perspectives in medicine. 2014 May 1:4(5):. doi: 10.1101/cshperspect.a017046.
18. Kleinegger CL, Hammond HL, Finkelstein MW. Oral mucosal hyperpigmentation secondary to antimalarial drug therapy. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. 2000 Aug:90(2):189-94
19. Sant'Ambrogio S, Connelly J, DiMaio D. Minocycline pigmentation of heart valves. Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology. 1999 Nov-Dec:8(6):329-32
20. Weiss SR, Lim HW, Curtis G. Slate-gray pigmentation of sun-exposed skin induced by amiodarone. Journal of the American Academy of Dermatology. 1984 Nov:11(5 Pt 1):898-900.